Media & Events » In the News Archive - 2008 » Brainsway interim trial for blepharospasm successful

Brainsway interim trial for blepharospasm successful

Jan. 20, 2008
Source: Gali Weinreb, Globes

Brainsway Ltd. (TASE:BRIN) has released preliminary results of its Phase IIa trial for the use of its transcranial magnetic stimulation (TMS) to treat blepharospasm - involuntary blinking. The results showed improvement in both subjective feelings of blinking and in the blink reflex recovery curve and abnormal brainstem hyper-excitability tests.

The trial was conducted jointly with the US National Institute of Health unit National Institute of Neurological Disorders and Stroke. It included 12 patients. The trial is one of the series of fairly small effectiveness tests that Brainsway is conducting before deciding which larger and more expensive treatments to pursue at multiple medical centers.

There are a wide range of treatments for blepharospasm, ranging from food supplements, drug treatments, and surgery to paralyze the eyelid muscles. Brainsway believes that the results of the trial demonstrate that TMS corrects hyper-excitability of the brainstem.

News Archive

Did You Know?

  • The Hebrew University ranks 12th worldwide in biotechnology patents.
     
  • $2 billion in annual sales are generated from two life science products originating from scientific innovation at the Hebrew University of Jerusalem. These include Exelon (marketed by Novartis) for the treatment of Alzheimer’s disease and Doxil (marketed by J&J) for the treatment of cancer..